Sclerotherapy Market Size Analysis:

The Sclerotherapy Market Size was valued at USD 1.13 Billion in 2023 and is expected to reach USD 1.68 Billion by 2032 and grow at a CAGR of 4.50% over the forecast period 2024-2032. This report identifies the increasing incidence and prevalence of varicose veins and chronic venous disorders as the main driver of the growing use of sclerotherapy treatments. The research investigates treatment preferences, presenting the trend toward minimally invasive interventions and the increasing popularity of foam sclerotherapy compared to conventional procedures. Also, it investigates healthcare spending on sclerotherapy, highlighting the influence of insurance coverage and out-of-pocket expenditures on the accessibility of treatments. The review also examines advances in technology, such as the creation of more effective sclerosants and image-guidance methods, that are improving treatment outcomes and patient results.

Sclerotherapy Market Dynamics

Drivers 

• The increasing prevalence of varicose veins and chronic venous disorders (CVDs), which affect over 30% of the global adult population.

Increased rates of sedentary lifestyles, obesity, and aging populations have contributed to a rise in demand for minimally invasive procedures such as sclerotherapy. Technological breakthroughs, including ultrasound-guided foam sclerotherapy, have made treatment more accurate, hence contributing to increased adoption by healthcare providers. Furthermore, increasing cosmetic vein treatment and non-surgical procedure awareness is boosting patient choice towards sclerotherapy compared to traditional vein-stripping operations. Positive reimbursement policies and regulatory clearances, including FDA-approved Polidocanol (Asclera) and Sodium Tetradecyl Sulfate (STS) injections, also propel market growth. Pharmaceutical firms are constantly investing in research and development to improve sclerosant products, making the procedures safer and more efficient. The growing number of outpatient vein clinics and specialized vascular centers have also helped boost Sclerotherapy market. Additionally, increasing popularity of aesthetic vein treatments among younger groups as a result of social media pressures is driving procedural volumes. The combination of robotic-assisted sclerotherapy and artificial intelligence-based imaging technologies will further enhance market growth in the future years.

Restraints

• The sclerotherapy market faces restraints due to the potential side effects and complications associated with the procedure.

Some of these are hyperpigmentation, allergic reactions, blood clot formation, and ulceration, posing worries to both patients and doctors. Furthermore, the absence of qualified professionals in advanced sclerotherapy procedures has also limited the growth of the market, especially in developing nations. Although a minimally invasive procedure, however, some of the patients instead choose other processes like laser treatment and endovenous ablation, which result in quicker recoveries and have fewer side effects. In addition, high regulatory standards for drug approvals, clinical trials, and quality controls have hindered the launch of new sclerosant products across different markets. Cost is another major consideration since sclerotherapy procedures are usually not comprehensively covered by insurance, resulting in a high out-of-pocket cost for patients. Certain sclerosants, including Polidocanol and Sodium Tetradecyl Sulfate (STS), need careful handling and administration procedures, thus adding to operational expenses for clinics. Further, unreliable treatment results, particularly among patients with critical venous diseases, have resulted in doubts over the long-term effectiveness of sclerotherapy. All these factors cumulatively constrain the potential growth of the market even with increased demand.

Opportunities

• Increasing medical tourism, particularly in countries such as India, Thailand, and Mexico, where patients seek cost-effective vein treatments.

The emergence of bioengineered sclerosants with improved efficacy and fewer side effects is likely to transform the industry. Furthermore, the increasing use of combination therapies—like sclerotherapy in combination with laser ablation—provides better patient outcomes, thus making the procedure more appealing. The increasing popularity of home-based or self-administered sclerotherapy kits, particularly for spider vein treatments, may create new revenue streams for industry players. Pharmaceutical firms are investing in the next-generation sclerosants, including microsphere-based and nanoparticle-enriched solutions, that improve treatment accuracy and efficacy. Growing healthcare spending and government programs encouraging minimally invasive treatments also create growth opportunities. The growth of e-commerce platforms for the distribution of sclerosants is increasing the availability of these products among healthcare providers globally. Cooperative agreements between biotech companies and universities to engineer new sclerotherapy methods are also likely to propel long-term market expansion. Moreover, adoption of artificial intelligence (AI) in vascular imaging for improved procedural efficiency is opening new horizons for industry growth. These factors as a whole suggest high chances of future growth in the sclerotherapy market.

Challenges

• The variability in treatment efficacy and recurrence rates, which can lead to patient dissatisfaction and reluctance to undergo the procedure.

Research indicates that between 20-30% of treated varicose veins can develop recurrence, necessitating further treatments. The second greatest challenge is the absence of uniform treatment protocols among various regions, which contributes to procedural variability in techniques and patient experiences. The market is also short of specialists who have been trained in advanced sclerotherapy techniques, making it unavailable in rural and underserved regions. High reliance on doctor skill implies that procedural success rates differ substantially, influencing market confidence. Patient misconceptions about sclerotherapy safety and efficacy are another issue, which can discourage adoption despite increasing awareness. Insufficient public reimbursement policies in some countries limit the ability of lower-income patients to access treatment, which further inhibits market penetration. In addition, competition from other treatments like radiofrequency ablation, laser treatment, and surgical procedures is a significant barrier to market expansion. Lastly, supply chain disruptions, especially during international crises like the COVID-19 pandemic, have impacted the manufacture and distribution of sclerosant drugs, which in turn have affected procedural volumes globally.

Sclerotherapy Market Segmentation Analysis

By Type

The Foam Sclerotherapy market led the sclerotherapy industry in 2023, contributing the highest revenue share. The use of foam procedures is more effective than the use of liquid sclerotherapy because they can displace more blood within the vein and create better contact with the vessel wall. Foam sclerotherapy can also treat more extensive varicose veins, making it commonly used by doctors and patients.

The Ultrasound Sclerotherapy segment is expected to be the most rapidly growing segment during the forecast period. The rising demand for ultrasound-guided procedures is based on their greater accuracy and efficiency in treating deeper or more complex varicose veins. The expanding availability of advanced imaging technologies and increasing demand for minimally invasive procedures are major drivers for its fast growth.

By Agents

The Detergents segment dominated the Sclerotherapy market in 2023 with a 39.9% share of revenues and was the most popular sclerosant type. Agents that are detergent-based, such as Polidocanol and Sodium Tetradecyl Sulfate (STS), are the first choice because they are very effective in obliterating veins and have a lesser rate of adverse effects. The fact that they can formulate stable foam makes them even more market leaders.

The Osmotic Agents segment is likely to be the most rapidly growing category in the years to come. Osmotic sclerosants, which work by dehydrating endothelial cells, are gaining popularity because of their potential efficacy in certain situations where detergent agents are not appropriate. Increasing research into substitute sclerosants and increasing demand for personalized treatment options are likely to propel this segment's growth.

By Application

The Hemorrhoids segment led the sclerotherapy market in 2023, with the highest revenue share. Sclerotherapy has become a commonly used non-surgical procedure for hemorrhoids, especially among patients looking for minimally invasive interventions. The rising incidence of hemorrhoidal disease owing to sedentary lifestyles, dietary patterns, and aging populations has played a major role in this segment's market leadership.

The Varicose Veins segment is also expected to have the highest growth during the forecast period. Owing to a growing number of patients with chronic venous disorders, especially resulting from lifestyle disorders and obesity, demand for sclerotherapy as an effective yet less invasive cure is increasing quickly. The improving knowledge about cosmetic vein treatment combined with improvements in the technique used in the process is expected to spur the segment growth in future years.

Sclerotherapy Market Regional Insights

North America led the sclerotherapy market globally in 2023, with a 43.5% share of the total revenue. The dominance of the region is due to the high incidence of varicose veins and chronic venous diseases, fueled by aging populations, obesity, and sedentary lifestyles. The prevalence of well-established healthcare infrastructure, positive reimbursement policies, and the robust presence of prominent market players has also spurred the uptake of sclerotherapy procedures. The United States, in specific, is the biggest contributor to the North American market, owing to growing patient preference for minimally invasive therapies and increased consciousness of vein disorders. The escalating need for therapeutic and aesthetic vein treatments coupled with advanced technologies like ultrasound-assisted sclerotherapy has also driven market growth.

Asia-Pacific is expected to be the highest-growing segment during the forecast period, supported by rising healthcare spends, growing disposable incomes, and an expanding patient pool with varicose veins and hemorrhoids. China, India, and Japan are among the countries witnessing fast growth in medical tourism and the use of sophisticated sclerotherapy treatments, especially in urban areas. Further, the increasing knowledge of non-surgical treatment methods for veins and a growing number of specialist vascular clinics are anticipated to boost the growth of the sclerotherapy market in the region.

Key Players in the Sclerotherapy Market

• LGM Pharma

• Troikaa

• Viatris Inc.

• Omega Pharmaceuticals Pvt. Ltd.

• Merz Pharma

• ENDO-FLEX GmbH

• Perrigo Company plc

• Medi-Globe GmbH

• Medtronic

• AngioDynamics

Recent Developments in the Sclerotherapy Market

• In July 2024, Medtronic and SWIZTON Medcare collaborated to establish their first specialized vein clinic in India at Aveksha Hospital, Bengaluru, aiming to provide advanced varicose vein treatments. This partnership marks a significant expansion in vein care services, integrating cutting-edge technologies in collaboration with leading hospitals.